查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1992053

互聯藥物輸送設備市場：按設備類型、藥物類型、最終用戶和分銷管道分類－2026-2032年全球預測

Connected Drug Delivery Devices Market by Device Type, Drug Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，連網藥物輸送設備市場價值將達到 49.8 億美元，到 2026 年將成長至 58.1 億美元，到 2032 年將達到 167.5 億美元，複合年成長率為 18.90%。

主要市場統計數據
基準年 2025 49.8億美元
預計年份：2026年 58.1億美元
預測年份 2032 167.5億美元
複合年成長率 (%) 18.90%

這清楚地表明，互聯互通、以患者為中心的設計以及監管進步是如何融合在一起，從而改變藥物輸送設備和臨床路徑的。

互聯藥物輸送設備透過將感測器、軟體和連接功能整合到傳統輸送平台中，重新定義了藥物、患者和醫療保健系統之間的聯繫點。隨著臨床路徑轉向分散式醫療和基於價值的治療結果轉變，能夠收集用藥依從性、劑量和情境相關生理數據的設備對於治療方案的發展變得至關重要。這項轉變的驅動力在於圍繞低功耗電子裝置、安全無線通訊協定以及作為醫療設備的軟體等相關監管對話的日趨成熟，這使得製造商能夠從獨立硬體轉向能夠為臨床決策提供資訊的整合解決方案。

找出正在加速藥物輸送數位整合並重新定義經營模式的核心技術、監管和經濟變革。

從組件供應鏈到終端用戶行為，互聯藥物輸送的格局正受到多項變革性變化的影響而重塑。首先，感測器和嵌入式分析技術的整合，正使設備從被動式給藥裝置轉變為主動式資料來源，從而實現封閉回路型護理和自適應給藥策略。這項技術進步也正在推動臨床醫生的觀念轉變，他們越來越依賴持續數據來最佳化治療方案並驗證其在實際應用中的療效。

分析 2025 年美國關稅將如何重塑整個互聯藥物輸送生態系統的供應鏈、價格壓力和產品設計選擇。

美國於2025年宣布的關稅措施的累積影響，正對全球互聯藥物輸送設備的供應鏈、零件採購和定價策略產生重大影響。這些關稅推高了電子元件、特殊聚合物和子組件的投入成本，而這些產品通常產自受影響地區，迫使製造商重新評估供應商所在地，並加快對替代供應商的認證。隨著各公司採取行動，許多公司正在推進區域籌資策略，增加庫存緩衝，並談判長期合約以穩定採購成本。

基於細分市場的分析揭示了設備子類型、治療領域、醫療保健環境和通路如何共同決定開發重點和商業策略。

基於細分框架的洞察揭示了每種醫療設備類型、給藥方式、終端用戶和分銷管道的不同成長要素和發展重點。根據醫療設備類型，該生態系統包括輸液幫浦、吸入器、注射器、鼻噴霧和經皮貼片。在輸液幫浦領域，腸道餵食幫浦、胰島素幫浦和病人自控式鎮痛幫浦（PCA幫浦）各自有不同的臨床介面和資料需求，要求開發人員根據使用環境和使用者熟練程度最佳化連接解決方案和安全功能。吸入器領域包括乾粉吸入器、定量吸入器和霧化器，其不同的操作機制和氣溶膠生成方式對每種產品的感測器整合和劑量檢驗技術提出了獨特的要求。

區域策略挑戰概述了管理體制、支付方期望和醫療保健系統的成熟度如何影響全球範圍內的採用和商業化。

區域趨勢對互聯藥物輸送設備的監管預期、報銷途徑和部署模式有顯著影響。在美洲，醫療保健系統的特徵是公立和私立支付方並存，治療效果和成本效益的證據備受重視。在這種環境下，能夠提高用藥依從性、減少住院次數並與電子健康記錄 (EHR) 系統整合的解決方案備受推崇。在美洲營運的製造商通常會優先考慮符合互通性標準、支付方協議以及與綜合醫療保健網路直接夥伴關係的經營模式。

本文探討了平台思維、對設備性能的追求以及夥伴關係主導的價值創造如何重塑競爭定位，並審視了企業的策略行動和競爭方法。

互聯藥物傳輸領域的企業策略展現出差異化競爭格局，包括基於平台的生態系統、設備性能專業化以及與服務交付的垂直整合。一些公司強調模組化硬體設計，並結合方便用戶使用的軟體平台，以吸引合作夥伴並建立可擴展的第三方應用生態系統。這種策略旨在透過降低整合門檻並實現與醫院IT系統和遠端監控供應商的互通性來擴大部署規模。另一方面，有些公司則專注於從極高的層面滿足特定的臨床需求，並大力投資人體工學、專有感測技術和檢驗的臨床工作流程，以確立自身作為首選供應商的地位。

為產品負責人、銷售團隊和供應鏈負責人提供實用建議，以加快部署速度並降低營運和監管風險。

產業領導者應採取一系列綜合措施，在管控營運風險的同時，充分挖掘互聯藥物輸送設備的價值。首先，從研發初期就融入以使用者為中心的設計理念和臨床工作流程整合，確保設備滿足實際應用需求，並最大限度地降低訓練負擔。其次，在設計工作的同時，建立模組化架構，實現元件更換和快速迭代，從而減輕供應鏈中斷和關稅相關成本波動對業務的影響。最後，投資嚴格的網路安全措施和完善的軟體生命週期流程，以滿足監管要求並保障病人安全。

我們採用透明的混合方法研究途徑，結合相關人員訪談、技術評估和文件分析，檢驗可操作的見解和方案。

本調查方法採用混合式方法，結合質性訪談、技術分析和二手資料研究，以得出檢驗的結論。主要工作包括對臨床醫生、採購負責人、醫療設備工程師、監管專家和保險公司進行結構化訪談，以了解實際應用障礙、技術偏好和報銷考慮。技術評估則著重檢視醫療設備架構、連接選項、安全框架以及與電子健康記錄 (EHR) 和遠端監測平台的整合路徑，以識別應用限制和機會。

策略結論簡潔地總結了技術創新、營運韌性和實證商業化之間的平衡，以實現永續的成功。

互聯藥物傳輸領域兼具技術潛力與營運複雜性，需要周詳的策略規劃。感測器技術、無線連接和分析技術的進步為提高用藥依從性、實現個人化劑量和驗證治療效果鋪平了道路，從而推進以患者為中心的醫療服務。同時，面對監管要求、供應鏈趨勢和商業性支付模式的變化，製造商必須協調並統一產品設計、證據產生和定價策略，以確保永續推廣應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 互聯藥物輸送設備市場：依設備類型分類

  • 點滴幫浦
    • 腸內泵
    • 胰島素幫浦
    • PCA泵浦
  • 吸入器
    • 乾粉吸入器
    • 定量吸入器
    • 噴霧器
  • 注射裝置
    • 自動注射器
    • 筆式注射器
    • 安全注射器
    • 標準注射器
  • 鼻噴霧
    • 手動噴霧
    • 霧化噴霧
  • 經皮吸收貼劑
    • 矩陣補丁
    • 水庫補丁

第9章 依藥物類型分類的互聯藥物輸送裝置市場

  • 生物製藥
  • 生物相似藥
  • 小分子藥物
  • 疫苗

第10章 聯網藥物輸送設備市場：依最終用戶分類

  • 門診部
  • 診所
  • 居家照護
  • 醫院

第11章 互聯藥物輸送設備市場：依分銷管道分類

  • 線上
  • 離線

第12章 互聯藥物輸送設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 互聯藥物傳輸設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 互聯藥物輸送設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國互聯藥物傳輸設備市場

第16章：中國互聯藥物傳輸設備市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Adherium Limited
  • AptarGroup, Inc.
  • Becton, Dickinson, and Company
  • Cognita Labs LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Findair Sp. z oo
  • Gerresheimer AG
  • Medtronic PLC
  • Merck KGaA
  • Molex LLC
  • Novartis AG
  • Novo Nordisk A/S
  • OPKO Health, Inc.
  • Otsuka America, Inc.
  • Presspart Verwaltungs-GmbH
  • ResMed Inc.
  • SHL Medical AG
  • Sulzer Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • West Pharmaceutical Services, Inc.
  • Ypsomed Holding
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-3C68ED2D0A4A

The Connected Drug Delivery Devices Market was valued at USD 4.98 billion in 2025 and is projected to grow to USD 5.81 billion in 2026, with a CAGR of 18.90%, reaching USD 16.75 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.98 billion
Estimated Year [2026] USD 5.81 billion
Forecast Year [2032] USD 16.75 billion
CAGR (%) 18.90%

A clear framing of how connectivity, patient-centric design, and regulatory evolution are converging to transform drug delivery devices and clinical pathways

Connected drug delivery devices are redefining the interface between therapeutics, patients, and healthcare systems by embedding sensors, software, and connectivity into traditional delivery platforms. As clinical pathways shift toward decentralized care and value-based outcomes, devices that capture adherence, dose administration, and contextual physiologic data are becoming integral to therapeutic regimens. This transformation is powered by advances in low-power electronics, secure wireless protocols, and a maturing regulatory dialogue around software as a medical device, enabling manufacturers to move beyond standalone hardware toward integrated solutions that inform clinical decision making.

Adoption is being driven by converging pressures: clinicians seek reliable adherence data to optimize treatment, payers demand proof of value, and patients favor convenience and autonomy. As a result, product development teams are rebalancing priorities to include user experience, interoperability with electronic health records, and cybersecurity by design. In parallel, commercialization strategies increasingly emphasize partnerships with digital health platforms, remote monitoring services, and specialty pharmacies. These shifts require manufacturers and stakeholders to rethink R&D pipelines, quality systems, and post-market surveillance to manage both clinical and digital performance.

Identification of the core technological, regulatory, and economic shifts that are accelerating digital integration and redefining commercial models in drug delivery

The landscape for connected drug delivery is being reshaped by several transformative shifts that extend from component supply chains to end-user behavior. First, the integration of sensors and embedded analytics is moving devices from passive dispensers to active data sources that enable closed-loop care and adaptive dosing strategies. This technical evolution is accompanied by a cultural shift among clinicians who increasingly rely on continuous data to fine-tune therapies and to demonstrate real-world effectiveness.

Second, reimbursement and procurement models are beginning to reward outcomes rather than devices alone, encouraging developers to bundle devices with services and digital therapeutics. This economic shift prompts manufacturers to design products that generate measurable value across the patient journey. Third, regulatory frameworks are adapting to software-driven functions, accelerating pathways for connected devices while simultaneously raising expectations for cybersecurity, interoperability, and post-market surveillance. Stakeholders must therefore implement robust lifecycle management processes for software updates and real-world performance monitoring.

Finally, the end-user environment is expanding beyond hospitals into homes and ambulatory settings, requiring devices to be intuitive, safe for non-clinical users, and compatible with diverse distribution channels. Collectively, these forces favor agile development models, strategic alliances with technology providers, and a relentless focus on human-centered design to ensure clinical adoption and long-term engagement.

Examination of how the 2025 United States tariff measures are reshaping supply chains, pricing pressure, and product design choices across connected drug delivery ecosystems

The cumulative impact of the United States tariffs announced in 2025 has introduced material considerations for global supply chains, component sourcing, and pricing strategies for connected drug delivery devices. Tariffs have elevated input costs for electronic components, specialized polymers, and subassemblies that are often manufactured in tariff-affected jurisdictions, prompting manufacturers to reassess supplier footprints and to accelerate qualification of alternative vendors. As firms adapt, many are pursuing regional sourcing strategies, increasing inventory buffers, and negotiating long-term agreements to stabilize procurement costs.

These adjustments have operational effects beyond unit costs. Product development timelines can extend due to new supplier validation, while inventory management requires a higher degree of coordination between procurement, production, and distribution teams. In addition, tariff-induced cost pressure intensifies scrutiny of product architectures, encouraging designers to optimize bill-of-materials and to evaluate modular designs that allow substitution of higher-cost elements. From a strategic perspective, some companies are exploring partial onshoring of assembly or final integration steps to mitigate tariff exposure and to maintain supply continuity for critical clinical accounts.

The tariffs also influence commercial dynamics. Payers and procurement officers may push for price concessions or for outcomes-based contracts that shift financial risk. Consequently, manufacturers face a dual imperative: preserve clinical and digital performance while containing delivered costs through design efficiencies, supplier diversification, and operational resilience. Taken together, these measures aim to protect access and competitiveness in a trade environment that has introduced elevated uncertainty.

Segment-specific intelligence revealing how device subtypes, therapeutic classes, care settings, and distribution pathways jointly determine development priorities and commercial strategies

Insights drawn from the segmentation framework reveal differentiated growth drivers and development priorities across device types, drug modalities, end users, and distribution channels. Based on Device Type, the ecosystem encompasses Infusion Pumps, Inhalers, Injection Devices, Nasal Spray, and Transdermal Patch. Within infusion pumps, Enteral Pumps, Insulin Pumps, and PCA Pumps present distinct clinical interfaces and data requirements, forcing developers to tailor connectivity solutions and safety features according to use setting and user proficiency. The inhaler segment includes Dry Powder Inhalers, Metered Dose Inhalers, and Nebulizers, each imposing unique constraints on sensor integration and dose verification technology due to differences in actuation mechanics and aerosol generation.

Injection Devices are studied across Autoinjectors, Pen Injectors, Safety Syringes, and Standard Syringes, where user ergonomics, dose accuracy, and needle safety mechanisms influence the integration of electronics and adherence-tracking capabilities. Nasal Spray formats subdivide into Manual Spray and Nebulized Spray, a distinction that matters for aerosol characterization, device-to-drug compatibility, and real-world administration patterns. Transdermal Patch modalities, including Matrix Patch and Reservoir Patch, demand attention to skin adhesion, reservoir control, and delivery kinetics, which in turn shape sensor placement and complementing analytics.

Based on Drug Type, the analysis differentiates Biologics, Biosimilars, Small Molecule, and Vaccines, acknowledging that biologic therapies often require cold chain considerations, precision dosing, and compatibility with infusion or injection platforms. Based on End User, insights span Ambulatory Care Centers, Clinics, Home Care, and Hospitals, clarifying how user competencies and care workflows inform training, device ruggedness, and remote support needs. Based on Distribution Channel, the study considers Direct Sales, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, highlighting how channel economics and customer touchpoints affect packaging, documentation, and post-sale digital service models. By aligning product architecture and commercial approaches to these intersecting segments, stakeholders can prioritize investments that address the highest-value combinations of device type, drug modality, care setting, and distribution pathway.

Regional strategic imperatives outlining how regulatory regimes, payer expectations, and health system maturity shape adoption and commercialization across global regions

Regional dynamics exert strong influence on regulatory expectations, reimbursement pathways, and adoption patterns for connected drug delivery devices. In the Americas, healthcare systems are characterized by a mix of private and public payers with high emphasis on evidence of outcomes and cost-effectiveness; this environment incentivizes solutions that demonstrate adherence improvement, reduced hospital utilization, and integration with electronic health records. Manufacturers operating in the Americas often prioritize interoperability standards, commercial models that align with payer contracts, and direct partnerships with integrated delivery networks.

In Europe, Middle East & Africa, heterogeneity across regulatory regimes and procurement processes requires nuanced entry strategies. European regulators and health technology assessment bodies focus on clinical and economic value, driving manufacturers to produce robust real-world evidence and to adapt to centralized and decentralized reimbursement landscapes. The Middle East & Africa region presents opportunities for leapfrogging traditional infrastructure through mobile-enabled solutions, but also demands attention to distribution logistics and localized training programs.

Asia-Pacific encompasses a broad spectrum of maturity from advanced digital health infrastructure to rapidly developing healthcare markets. Adoption here is influenced by government initiatives promoting digital health, a growing emphasis on home-based care, and cost-sensitive procurement policies. Manufacturers targeting Asia-Pacific need to balance global standards with local regulatory compliance, optimize supply chains for regional hubs, and collaborate with local partners to tailor user interfaces, languages, and service models to diverse patient populations.

Strategic company behaviors and competitive approaches demonstrating how platform thinking, focused device excellence, and partnership-led value creation are reshaping competitive positioning

Company strategies in the connected drug delivery domain reveal competing approaches to differentiation, including platform-based ecosystems, focused device excellence, and vertical integration with service offerings. Some firms emphasize modular hardware designs paired with developer-friendly software platforms to attract partners and to create extensible ecosystems for third-party applications. This approach seeks to scale adoption by lowering integration barriers and enabling interoperability with hospital IT and remote monitoring vendors. Other companies concentrate on solving a narrow clinical need exceptionally well, investing heavily in human factors engineering, proprietary sensing technologies, and validated clinical workflows to secure preferred provider status.

A third strategic pathway involves closer alignment with pharmaceutical sponsors and specialty pharmacies, offering co-developed combination products or data-enabled adherence programs that support value-based contracting. Across strategies, leading organizations are strengthening capabilities in cybersecurity, regulatory software lifecycle management, and post-market evidence generation. Competitive advantage increasingly depends on the ability to operationalize data into clinical insights and to present clear value propositions to payers and providers. Partnerships, acquisitions, and collaborative R&D remain common mechanisms to accelerate capability acquisition while spreading development risk across technical and regulatory domains.

Action-oriented recommendations for product leaders, commercial teams, and supply chain executives to accelerate adoption and mitigate operational and regulatory risk

Industry leaders should adopt an integrated set of actions to capture value from connected drug delivery devices while managing operational risks. Begin by embedding user-centered design and clinical workflow integration early in development to ensure devices meet real-world needs and minimize training burdens. Parallel to design work, establish modular architectures that permit component substitution and rapid iteration, which reduces the business impact of supply chain disruptions and tariff-related cost volatility. Invest in rigorous cybersecurity practices and a documented software lifecycle process to meet regulatory expectations and to protect patient safety.

Commercially, pursue bundled value propositions that link device performance to measurable health outcomes and align pricing with payer priorities. Cultivate partnerships with digital health vendors, specialty pharmacies, and hospital IT providers to accelerate interoperability and to create integrated service offerings. Operational resilience requires a diversified supplier base, strategic inventory planning, and contingency sourcing for critical electronic components. Finally, commit to real-world evidence programs and stakeholder education to demonstrate clinical utility and to accelerate adoption across home care, ambulatory, and hospital settings. These combined actions will enhance the ability to deliver clinically meaningful, economically viable connected solutions at scale.

A transparent mixed-methods research approach combining stakeholder interviews, technical assessments, and document analysis to validate practical insights and scenarios

The research methodology is grounded in a mixed-methods approach that combines qualitative interviews, technical analyses, and secondary research to produce validated insights. Primary engagement included structured interviews with clinicians, procurement officers, device engineers, regulatory specialists, and payers to capture practical barriers to adoption, technology preferences, and reimbursement considerations. Technical evaluation assessed device architectures, connectivity options, security frameworks, and integration pathways with electronic health records and remote monitoring platforms to identify implementation constraints and opportunities.

Secondary research complemented primary findings through regulatory guidance documents, standards bodies' publications, patent landscape reviews, and company disclosures to triangulate technology maturity and strategic direction. Data validation employed cross-checks between interview themes and documented evidence, while scenario testing explored implications of supply chain shocks, tariff changes, and regulatory shifts. The methodology emphasizes transparency in assumptions, traceable source citations for factual claims, and iterative validation with subject-matter experts to ensure relevance and practical applicability for decision-makers operating across development, regulatory, and commercial functions.

A concise synthesis of strategic conclusions emphasizing the balance of technical innovation, operational resilience, and evidence-driven commercialization for sustained success

The connected drug delivery landscape presents a combination of technological promise and operational complexity that demands deliberate strategy. Advancements in sensor technologies, wireless connectivity, and analytics create pathways to improve adherence, personalize dosing, and demonstrate outcomes, thereby advancing patient-centric care. At the same time, evolving regulatory expectations, supply chain dynamics, and commercial payment models require manufacturers to align product design, evidence generation, and pricing strategies in a coordinated manner to realize sustained adoption.

Success will depend on the ability to integrate human-centered design with robust digital and cybersecurity practices, to engineer resilient supply chains in the face of trade disruptions, and to develop commercial models that clearly link device-enabled data to clinical and economic value. Organizations that balance technical excellence with pragmatic partnerships and evidence-based commercialization will be best positioned to convert innovation into tangible improvements in patient care and system efficiencies. In this context, timely, focused actions on design, sourcing, and stakeholder alignment will determine which players gain durable advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Connected Drug Delivery Devices Market, by Device Type

  • 8.1. Infusion Pumps
    • 8.1.1. Enteral Pumps
    • 8.1.2. Insulin Pumps
    • 8.1.3. PCA Pumps
  • 8.2. Inhalers
    • 8.2.1. Dry Powder Inhalers
    • 8.2.2. Metered Dose Inhalers
    • 8.2.3. Nebulizers
  • 8.3. Injection Devices
    • 8.3.1. Autoinjectors
    • 8.3.2. Pen Injectors
    • 8.3.3. Safety Syringes
    • 8.3.4. Standard Syringes
  • 8.4. Nasal Spray
    • 8.4.1. Manual Spray
    • 8.4.2. Nebulized Spray
  • 8.5. Transdermal Patch
    • 8.5.1. Matrix Patch
    • 8.5.2. Reservoir Patch

9. Connected Drug Delivery Devices Market, by Drug Type

  • 9.1. Biologics
  • 9.2. Biosimilars
  • 9.3. Small Molecule
  • 9.4. Vaccines

10. Connected Drug Delivery Devices Market, by End User

  • 10.1. Ambulatory Care Centers
  • 10.2. Clinics
  • 10.3. Home Care
  • 10.4. Hospitals

11. Connected Drug Delivery Devices Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Connected Drug Delivery Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Connected Drug Delivery Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Connected Drug Delivery Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Connected Drug Delivery Devices Market

16. China Connected Drug Delivery Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Adherium Limited
  • 17.7. AptarGroup, Inc.
  • 17.8. Becton, Dickinson, and Company
  • 17.9. Cognita Labs LLC
  • 17.10. Eli Lilly and Company
  • 17.11. F. Hoffmann-La Roche AG
  • 17.12. Findair Sp. z o. o.
  • 17.13. Gerresheimer AG
  • 17.14. Medtronic PLC
  • 17.15. Merck KGaA
  • 17.16. Molex LLC
  • 17.17. Novartis AG
  • 17.18. Novo Nordisk A/S
  • 17.19. OPKO Health, Inc.
  • 17.20. Otsuka America, Inc.
  • 17.21. Presspart Verwaltungs-GmbH
  • 17.22. ResMed Inc.
  • 17.23. SHL Medical AG
  • 17.24. Sulzer Ltd.
  • 17.25. Teva Pharmaceutical Industries Ltd.
  • 17.26. Viatris Inc.
  • 17.27. West Pharmaceutical Services, Inc.
  • 17.28. Ypsomed Holding
  • 17.29. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ENTERAL PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ENTERAL PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ENTERAL PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PCA PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PCA PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PCA PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY STANDARD SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY STANDARD SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY STANDARD SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MANUAL SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MANUAL SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MANUAL SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZED SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZED SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZED SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MATRIX PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. GCC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 193. GCC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 195. GCC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 196. GCC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 197. GCC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. GCC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. G7 CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. G7 CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. G7 CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 223. G7 CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 225. G7 CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 226. G7 CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 227. G7 CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. G7 CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. NATO CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. NATO CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 234. NATO CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 235. NATO CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 237. NATO CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. NATO CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)